Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2004;6 Suppl 10(Suppl 10):S13-8.

Overview of prostate-specific membrane antigen

Sam S Chang

Overview of prostate-specific membrane antigen

Sam S Chang. Rev Urol. 2004.

Abstract

Efforts to evaluate and discover diagnostic and therapeutic markers for prostate cancer continue. One of these, prostate-specific membrane antigen (PSMA), a transmembrane protein expressed in all types of prostatic tissue, remains a useful diagnostic and possibly therapeutic target. The radio-immunoconjugate form of the anti-PSMA monoclonal antibody 7E11 is used in the commercially available and US Food and Drug Administration-approved diagnostic tool, the ProstaScint(R) (Cytogen Corporation, Princeton, NJ) scan. Recent studies have demonstrated other possible useful roles for PSMA as a target, not only in prostate cancer, but in other malignancies.

PubMed Disclaimer

Figures

Figure 1
Figure 1
Schematic of prostate-specific membrane antigen.
Figure 2
Figure 2
Comparison of prostate-specific antigen (PSA) and prostate-specific membrane antigen (PSMA). RT-PCR, reverse transcriptase polymerase chain reaction.
See this image and copyright information in PMC

References

    1. Ross JS, Sheehan CE, Fisher HAG, et al. Correlation of primary tumor prostate-specific membrane antigen expression with disease recurrence in prostate cancer. Clin Cancer Res. 2003;9:6357–6362. - PubMed
    1. Horoszewicz JS, Kawinski E, Murphy GP. Monoclonal antibodies to a new antigenic marker in epithelial cells and serum of prostatic cancer patients. Anticancer Res. 1987;7:927–936. - PubMed
    1. Lopes AD, Davis WL, Rosenstraus MJ, et al. Immunohistochemical and pharmacokinetic characterization of the site-specific immunoconjugate CYT-356 derived from antiprostate monoclonal antibody 7E11-C5. Cancer Res. 1990;50:6423–6429. - PubMed
    1. Israeli RS, Miller WH, Jr, Su SL, et al. Sensitive nested reverse transcription polymerase chain reaction detection of circulating prostatic tumor cells: comparison of prostate-specific membrane antigen and prostate-specific antigen-based assays. Cancer Res. 1994;54:6306–6310. - PubMed
    1. Silver DA, Pellicer I, Fair WR, et al. Prostatespecific membrane antigen expression in normal and malignant human tissues. Clin Cancer Res. 1997;3:81–85. - PubMed

LinkOut - more resources